Evidence map›Paper›PMID 39592415›Full record

ArticleMolecular oncology2025

Viral mimicry evasion: a new role for oncogenic KRAS mutations.

Raymond Chen, Aobo He, Daniel D De Carvalho

Abstract read
In one paragraph

Article in Molecular oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Raymond ChenDepartment of Medical Biophysics, University of Toronto, Canada.
Aobo HeDepartment of Medical Biophysics, University of Toronto, Canada.ORCID 0000-0001-8609-0542
Daniel D De CarvalhoDepartment of Medical Biophysics, University of Toronto, Canada.ORCID 0000-0002-8572-5259

Funding

CIHR PJT-165986CIHR PJT-195663Princess Margaret Cancer Foundation
6 · The paper itself

Abstract

"Viral mimicry" refers to the induction of an innate immune response and interferon signaling by endogenous stimuli such as double-stranded RNA (dsRNA). This response has been shown to have strong cancer therapeutic potential, including by enhancing the effectiveness of immune checkpoint inhibition (ICI) therapies, and may represent a tumor suppression mechanism that needs to be overcome for malignant transformation to proceed. In a recent study, Zhou and colleagues identify KRAS, a frequently mutated oncogene, as a negative regulator of dsRNA and viral mimicry in an ICI-resistant colorectal cancer model. Oncogenic KRAS

Indexed as

Molecular MimicryMutationProto-Oncogene Proteins p21(ras)AnimalsHumansRNA, Double-StrandedKRAS protein, humanProto-Oncogene Proteins p21(ras)RNA, Double-Strandedcolorectal cancerDDX60dsRNAimmune checkpoint inhibitionKRASviral mimicry

Identifiers

PMID39592415
PMCPMC11792985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.